Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship.
Powe CE, Ricciardi C, Berg AH, Erdenesanaa D, Collerone G, Ankers E, Wenger J, Karumanchi SA, Thadhani R, Bhan I. · 2011
Read Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. by Powe CE, Ricciardi C, Berg AH, Erdenesanaa D, Collerone G, Ankers E, Wenger J, Karumanchi SA, Thadhani R, Bhan I. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3351032.txt.
Introduction
Powe and colleagues tested which form of vitamin D in the blood actually tracks with bone health. Clinicians usually measure total 25-hydroxyvitamin D, yet most of it circulates bound to a carrier protein, and the free or bioavailable fraction may be the part tissues can use.
In 49 healthy young adults, the researchers measured total, free, and bioavailable vitamin D alongside bone mineral density. The free and bioavailable fractions correlated with density, while the total level did not show the same relationship. The result challenges routine reliance on total vitamin D and suggests binding protein levels help explain differences between population groups.
Catalog record
| CREATOR | Powe CE, Ricciardi C, Berg AH, Erdenesanaa D, Collerone G, Ankers E, Wenger J, Karumanchi SA, Thadhani R, Bhan I. |
|---|---|
| YEAR | 2011 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Vitamin D–Binding Protein Modifies the Vitamin D–Bone Mineral Density Relationship By Camille E Powe, Catherine Ricciardi, Anders H Berg, Delger Erdenesanaa, Gina Collerone, Elizabeth Ankers, Julia Wenger, S Ananth Karumanchi, Ravi Thadhani, Ishir Bhan Published in: Journal of Bone and Mineral Research DOI: 10.1002/jbmr.387 ABSTRACT Abstract Studies examining the relationship between total circulating 25-hydroxyvitamin D [25(OH)D] levels and bone mineral density (BMD) have yielded mixed results. Vitamin D–binding protein (DBP), the major carrier protein for 25(OH)D, may alter the biologic activity of circulating vitamin D. We hypothesized that free and bioavailable 25(OH)D, calculated from total 25(OH)D, DBP, and serum albumin levels, would be more strongly associated with BMD than levels of total 25(OH)D. We measured total 25(OH)D, DBP, and serum albumin levels in 49 healthy young adults enrolled in the Metabolic Abnormalities in College-Aged Students (MACS) study. Lumbar spine BMD was measured in all subjects using dual-energy X-ray absorptiometry. Clinical, diet, and laboratory information also was gathered at this time. We determined free and bioavailable (free + albumin-bound) 25(OH)D using previously validated formulas and examined their associations with BMD. BMD was not associated with total 25(OH)D levels (r = 0.172, p = .236). In contrast, free and bioavailable 25(OH)D levels were positively correlated with BMD (r = 0.413, p = .003 for free, r = 0.441, p = .002 for bioavailable). Bioavailable 25(OH)D levels remained independently associated with BMD in multivariate regression models adjusting for age, sex, body mass index, and race (p = .03). It is concluded that free and bioavailable 25(OH)D are more strongly correlated with BMD than total 25(OH)D. These findings have important implications for vitamin D supplementation in vitamin D–deficient states. Future studies should continue to explore the relationship between free and bioavailable 25(OH)D and health outcomes. © 2011 American Society for Bone and Mineral Research. Keywords: Vitamin D, Vitamin D–binding protein, Bone mineral density, Free hormone hypothesis, Vitamin D deficiency INTRODUCTION Vitamin D deficiency is associated with decreased calcium absorption and elevated levels of parathyroid hormone (PTH),1 which may lead to excessive bone resorption.2 In some observational studies, higher levels of 25-hydroxyvitamin D [25(OH)D] have been linked to increased bone mineral density (BMD) and decreased risk of fracture.3–7 Additionally, several randomized, controlled trials suggest that vitamin D supplementation reduces the risk of fracture and increases BMD.8–14 However, not all observational studies have confirmed the relationship between 25-hydroxyvitamin D [25(OH)D] and BMD, especially in younger populations or racial minorities.15–19 Moreover, in several randomized trials, the effect of vitamin D supplementation on BMD or fracture risk has been modest,8 absent,20–22 or reversed.23 The free hormone hypothesis postulates that only hormones liberated from binding proteins enter cells and produce biologic action.24 25(OH)D and 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] circulate bound to vitamin D–binding protein (85% to 90%) and albumin (10% to 15%), with less than 1% of circulating hormone in its free form.25 In mice, vitamin D–binding protein (DBP) prolongs the serum half-life of 25(OH)D and protects against vitamin D deficiency by serving as a vitamin D reservoir.26 However, DBP also limits the biologic activity of injected 1,25(OH)2D3 in mice26 and inhibits the action of vitamin D on monocytes and keratinocytes in vitro.27, 28 The significance of circulating DBP levels with regard to vitamin D's biologic action in humans is unclear. The free fraction of 25(OH)D and the binding-affinity constants for 25(OH)D's interaction with DBP and albumin have been measured previously.29 Formulas for the calculation of free 25(OH)D levels based on serum concentrations of total 25(OH)D, DBP, and albumin have been developed based on these data. Measured and calculated values of free 25(OH)D are highly correlated.29 To determine whether DBP modifies the relationship between 25(OH)D levels and BMD, we measured serum levels of total 25(OH)D, DBP, and albumin in a group of healthy young adults and calculated levels of free and bioavailable (free + albumin bound) 25(OH)D using adaptations of previously validated formulas. We then determined whether free or bioavailable 25(OH)D levels are more strongly associated with lumbar spine BMD than total 25(OH)D levels in this population. MATERIALS AND METHODS Subject recruitment We conducted a cross-sectional study in a subset of healthy young adults enrolled in the Metabolic Abnormalities in College Students (MACS) study, a study designed to evaluate the prevalence of metabolic abnormalities in university students.30 Subjects were healthy 18- to 31-year-old male and female students from private universities in the Boston area. A total of 170 subjects were recruited through flyers posted throughout the Massachusetts Institute of Technology (MIT) campus and through targeted e-mails to random members of the student population. All subjects provided written informed consent. The study was approved by the MIT Committee on the Use of Humans as Experimental Subjects. Forty-nine subjects had sufficient sample for inclusion in this analysis, and their characteristics are presented in Table 1. [Table: Characteristics of the Study Population (n = 49)] Study visit Subjects were instructed to fast for 12 hours prior to admission to the MIT Clinical Research Center (CRC) as outpatients and underwent a baseline evaluation including a blood sample collection and various physiologic measurements. Structured interviews were conducted by study nurses to collect standard clinical information, minutes of exercise per week (in 30-minute increments), and medication/supplement use. Height was measured using a standing stadiometer (Holton, Ltd., Crymych, Dyfed, UK). Weight was measured using a calibrated scale (SECA, Hanover, MD, USA). Body mass index (BMI) was calculated as weight (kg)/[height (m)]2. Dietary information Subjects completed a written food record 1 week prior to the day of study, recording 4 full days of food intake, including one weekend day. During the study visit to the MIT CRC, a registered dietitian reviewed the food record with the subject to clarify the quantities and sources of food consumed. Dietary intake data then were analyzed using Nutrition Data System for Research software version 2006/2007 (Nutrition Coordinating Center, University of Minnesota, Minneapolis, MN, USA). Bone density measurement Subjects underwent total-body dual-energy X-ray absorptiometry (DXA; Hologic QDR-4500A, Hologic, Waltham, MA, USA) to determine total and regional BMD.31 Hologic phantoms were used to calibrate the instrument. We used lumbar spine BMD in this study as the measure of BMD. Lumbar spine BMD is a preferred site for the diagnosis of osteoporosis and the prediction of fracture. No hip BMD measurements were available.32, 33 Biochemical analysis Baseline blood samples were frozen at −80°C and stored for later analysis. 25(OH)D, serum calcium, albumin, and levels of parathyroid hormone (PTH) were measured in the Massachusetts General Hospital (MGH) clinical laboratories. 25(OH)D2 and 25(OH)D3 levels were measured by liquid chromatography–tandem mass spectrometry (LC-MS), with interassay coefficients of variation (CVs) of 9.1% for 25(OH)D2 and 8.6% for 25(OH)D3. Total 25(OH)D level was calculated as the sum of 25(OH)D2 level and 25(OH)D3 level. Intact PTH was measured by electrochemiluminescense immunoassay on the Cobas E160 automated analyzer (Roche Diagnostics, Indianapolis, IN, USA). The interassay CV for intact PTH measurement was 4.2%. Calcium and albumin levels were measured by dye-based photometric assays on an automated analyzer. DBP was measured in duplicate by commercial enzyme-linked immunosorbent assay (ELISA; Cat. No. DVDBP0, R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. The assay was conducted after diluting serum samples 1:2000 in Calibrator Diluent RD6-11 (Part No. 895489, R&D Systems). The interassay CV was